Safe Rule of 40
The Rule of 40 of Safe (ALSAF.PA) as of Nov 5, 2026 is -57.69 %. In the previous year, Rule of 40 was -57.81 % — a change of -0.20% (higher).
Get this data via API
Financial Data API
Rule of 40
-57.69 %
YoY
-0.20%
Last updated:
Rule of 40 of Safe is 2025 -57.69 % . Rule of 40 of Safe was 2024 -57.81 % . It decreases by -0.20% higher compared to the previous year.
The Safe Rule of 40 history
3 Years
10 Years
25 Years
Max
Rule of 40
Date
Rule of 40
Jan 1, 2018
-177,170.76 EUR
Jan 1, 2019
135,120.16 EUR
Jan 1, 2020
-204.44 EUR
Jan 1, 2021
-142.00 EUR
Jan 1, 2022
-73.02 EUR
Jan 1, 2023
-138.19 EUR
Jan 1, 2024
-57.81 EUR
Jan 1, 2025
-57.69 EUR
| YEAR | Rule of 40 | YoY |
|---|---|---|
| -57.69 % | -0.20% | |
| -57.81 % | -58.16% | |
| -138.19 % | +89.23% | |
| -73.02 % | -48.57% | |
| -142.00 % | -30.54% | |
| -204.44 % | -100.15% | |
| 135,120.16 % | -176.27% | |
| -177,170.76 % | +1.42% | |
| -174,695.19 % | -34.29% | |
| -265,840.42 % | -7.99% | |
| -288,929.49 % | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Safe Stock analysis
What does Safe do? Safe SA generates revenue through the development, production, and commercialization of spinal surgery products. The company offers SteriSpine PS, a Pedicle Screw System, and SteriSpine LC, a Lumbar Cage System, both designed for safe implant positioning and surgical access. These products feature quick change handles, dual trials, and impact removal mechanisms, utilizing polyarylamid material reinforced with 50% glass fibers. The primary buyers are healthcare providers and hospitals specializing in orthopaedic surgery, focusing on minimally invasive spinal procedures.
The firm's product portfolio targets spinal surgery segments requiring precise implant placement and efficient surgical workflows. SteriSpine PS and SteriSpine LC are marketed to medical professionals seeking reliable solutions for spinal stabilization. The company's focus on polyarylamid-based materials ensures durability and compatibility with surgical requirements. Sales are driven by the demand for advanced spinal surgery tools that enhance procedural safety and reduce operation times.
Safe SA's commercial strategy emphasizes direct sales to orthopaedic departments and surgical centers. The company's products are positioned as premium solutions within the spinal surgery market, catering to institutions prioritizing patient safety and surgical precision. By concentrating on a limited range of high-demand products, Safe SA maintains a focused approach to market penetration and customer satisfaction. Safe is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Safe stock
Rule of 40 of Safe is -57.69 % in 2025.
On Eulerpool you can find the complete historical development of Rule of 40 Safe since 2006 – with annual values, charts, and detailed analysis.
The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Quality — Safe
All Key Metrics — Safe
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth